Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
- PMID: 7513904
- DOI: 10.1126/science.7513904
Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
Abstract
Many tumors express tumor-specific antigens capable of being presented to CD8+ T cells by major histocompatibility complex (MHC) class I molecules. Antigen presentation models predict that the tumor cell itself should present these antigens to T cells. However, when conditions for the priming of tumor-specific responses were examined in mice, no detectable presentation of MHC class I-restricted tumor antigens by the tumor itself was found. Rather, tumor antigens were exclusively presented by host bone marrow-derived cells. Thus, MHC class I-restricted antigens are efficiently transferred in vivo to bone marrow-derived antigen-presenting cells, which suggests that human leukocyte antigen matching may be less critical in the application of tumor vaccines than previously thought.
Similar articles
-
Gene vaccination with naked plasmid DNA: mechanism of CTL priming.J Exp Med. 1996 Oct 1;184(4):1555-60. doi: 10.1084/jem.184.4.1555. J Exp Med. 1996. PMID: 8879229 Free PMC article.
-
Bone marrow-derived cells present MHC class I-restricted tumour antigens in priming of antitumour immune responses.Ciba Found Symp. 1994;187:229-40; discussion 240-4. doi: 10.1002/9780470514672.ch15. Ciba Found Symp. 1994. PMID: 7796673 Review.
-
Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?J Exp Med. 1996 Mar 1;183(3):769-76. doi: 10.1084/jem.183.3.769. J Exp Med. 1996. PMID: 8642281 Free PMC article.
-
Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells.Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8578-83. doi: 10.1073/pnas.93.16.8578. Proc Natl Acad Sci U S A. 1996. PMID: 8710913 Free PMC article.
-
On cross-priming of MHC class I-specific CTL: rule or exception?Eur J Immunol. 2002 Sep;32(9):2385-92. doi: 10.1002/1521-4141(200209)32:9<2385::AID-IMMU2385>3.0.CO;2-V. Eur J Immunol. 2002. PMID: 12207322 Review. No abstract available.
Cited by
-
Direct presentation regulates the magnitude of the CD8+ T cell response to cell-associated antigen through prolonged T cell proliferation.J Immunol. 2010 Sep 1;185(5):2763-72. doi: 10.4049/jimmunol.0903920. Epub 2010 Jul 26. J Immunol. 2010. PMID: 20660711 Free PMC article.
-
Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 Gag particles.J Virol. 2002 Aug;76(15):7544-53. doi: 10.1128/jvi.76.15.7544-7553.2002. J Virol. 2002. PMID: 12097567 Free PMC article.
-
CCL19 reduces tumour burden in a model of advanced lung cancer.Br J Cancer. 2006 Apr 10;94(7):1029-34. doi: 10.1038/sj.bjc.6603061. Br J Cancer. 2006. PMID: 16598185 Free PMC article.
-
alpha v beta3-dependent cross-presentation of matrix metalloproteinase-2 by melanoma cells gives rise to a new tumor antigen.J Exp Med. 2005 Jul 4;202(1):61-72. doi: 10.1084/jem.20042138. J Exp Med. 2005. PMID: 15998788 Free PMC article.
-
CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity.Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5561-6. doi: 10.1073/pnas.082107699. Epub 2002 Apr 2. Proc Natl Acad Sci U S A. 2002. PMID: 11929985 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
